Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib
| Autor: | Frank Jacobs, Loeckie de Zwart, I. Goris, Mario Monshouwer, Rao N.V.S. Mamidi, Lilian Y. Li, Italo Poggesi, Jan Snoeys, Peter Verboven, Ellen Scheers, Inneke Wynant |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Physiologically based pharmacokinetic modelling
Genotype CYP3A Antineoplastic Agents RM1-950 Pharmacology Models Biological Article Pharmacokinetics Quinoxalines Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme Inhibitors Humans Drug Interactions Pharmacology (medical) Growth factor receptor inhibitor CYP2C9 Cytochrome P-450 CYP2C9 Cytochrome P-450 Enzyme Inducers CYP3A4 biology Chemistry Research Cytochrome P450 Transporter Articles Orosomucoid Modeling and Simulation biology.protein Pyrazoles Therapeutics. Pharmacology |
| Zdroj: | CPT: Pharmacometrics & Systems Pharmacology CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 1107-1118 (2021) |
| ISSN: | 2163-8306 |
| Popis: | Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to α1‐acid glycoprotein (AGP) and is primarily metabolized by cytochrome P450 (CYP) 2C9 and 3A4. This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug–drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors and CYP3A4/CYP2C9 inducers on erdafitinib pharmacokinetics (PK) in patients with cancer exhibiting higher AGP levels and in populations with different CYP2C9 genotypes. Erdafitinib's DDI potential as a perpetrator for transporter inhibition and for time‐dependent inhibition and/or induction of CYP3A was also evaluated. The PBPK model incorporated input parameters from various in vitro and clinical PK studies, and the model was verified using a clinical DDI study with itraconazole and fluconazole. Erdafitinib clearance in the PBPK model consisted of multiple pathways (CYP2C9/3A4, renal, intestinal; additional hepatic clearance), making the compound less susceptible to DDIs. In poor‐metabolizing CYP2C9 populations carrying the CYP2C9*3/*3 genotype, simulations shown clinically relevant increase in erdafitinib plasma concentrations. Simulated luminal and enterocyte concentration showed potential risk of P‐glycoprotein inhibition with erdafitinib in the first 5 h after dosing, and simulations showed this interaction can be avoided by staggering erdafitinib and digoxin dosing. Other than a simulated ~ 60% exposure reduction with strong CYP3A/2C inducers such as rifampicin, other DDI liabilities were minimal and considered not clinically relevant. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|